Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Next Previous
Trial Profile

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rocatinlimab (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ROCKET-Horizon
  • Sponsors Amgen

Most Recent Events

  • 26 Feb 2025 According tot a Kyowa Kirin media release, the company announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting to be held in Orlando, Florida from March 7-11, 2025.
  • 25 Sep 2024 Primary endpoint (Achievement of 75% Reduction From Baseline in EASI Score (EASI 75) at Week 24) has been met, according to a Kyowa Kirin media release.
  • 25 Sep 2024 Primary endpoint (Achievement of a Validated Investigators Global Assessment for Atopic Dermatitis Score of 0 (Clear) or 1 (Almost Clear) with a 2 Point Reduction From Baseline (vIGA-AD 0/1) at Week 24) has been met, according to a Kyowa Kirin media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top